Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: weatherproof who wrote (36019)	6/17/2016 4:25:34 PM
From: allatwwk	1 Recommendation Recommended By dorightbythem Read Replies (1) \| Respond to of 63324

weather, your first 5 questions are interesting, question 6 is everything.

To: weatherproof who wrote (36019)	6/17/2016 7:50:07 PM
From: winners18	Read Replies (2) \| Respond to of 63324

os The reason y fda only requires RR or (RR and PFS??) data for aa so terminal ill pts would receive lifesaving medicine sooner. Just like immu-132 tnbc OS was measured at 14 months at the monent yet it had not reached 50%.Those pts cant wait for the os data to mature and they needed to be treated right away. I dont known what was going on with immunomedics management! They disclosed some information to the analyst regarding its fda meeting yet didnt put a news release on it and filed an sec filing on what was being said. IMHO, the co is waiting the partner to sign on and let it decide what is the next step.